Home
Storia in 2 fonti
BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
- ·
benzinga.com
BioLineRx Drug Shows Anti-Tumor Activity In Brain Tumor Animal Models - BioLine Rx (NASDAQ:BLRX)
BioLineRx shares new GLIX1 glioblastoma data showing anti-tumor activity, including in temozolomide-resistant cancer models.
- ·
morningstar.com
BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting